All In Biotech

Drug Trial Radar · NCT07568236

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

A Phase II Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) for Prostate Cancer (Fez-Cap)

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Dec 31, 2027

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.

Conditions

  • Vasomotor Symptoms
  • Prostate Cancer

Interventions

  • FezolinetantDrug

    Fezolinetant 45 mg orally once daily for 12 weeks.

  • PlaceboDrug

    Placebo orally once daily for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hot flush severityTime frame: Baseline, week 3, week 7 and week 11
  2. Daily hot flush scoreTime frame: Baseline, week 3, week 7 and week 11

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Shatin, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.